12 December 2024
Physiomics plc
("Physiomics" or the "Company")
Contract Award
Physiomics plc (AIM: PYC), a leading
mathematical modelling, data science and biostatistics company
supporting the development of new therapeutics and personalised
medicine solutions, is pleased to announce a new contract with its
long-standing client, Numab Therapeutics AG.
The project will involve the application of
Pharmacokinetic-Pharmacodynamic (PK/PD) modelling to inform the
Target Candidate Profile ("TCP") of a key asset in Numab
Therapeutic's pipeline. Delivery of the project is expected to
complete within the next 6 months.
This latest collaboration builds on Physiomics'
strong relationship with Numab Therapeutics AG and highlights its
expertise in using modelling and simulation approaches to
accelerate the development of innovative therapies across a range
of therapeutic areas and across the entire drug development
pathway, including early discovery and development.
Dr Peter Sargent, CEO of Physiomics,
commented:
"We are
excited to build on our partnership with Numab Therapeutics AG and
contribute to the advancement of this innovative therapy. This
collaboration highlights our growing ability to provide
comprehensive support to our clients, addressing critical
challenges and adding value at multiple stages of the drug
development process."
For more information about Physiomics and its
services, please visit www.physiomics.co.uk.
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines expertise
across Modelling & Simulation, Biostatistics, Data Science and
Bioinformatics, together with deep biology expertise, to help
biotech and pharma companies streamline their drug development
journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and
clinical studies. Through use of cutting-edge computational tools,
bespoke models and our proprietary Virtual Tumour technology, the
Physiomics team has informed the development of over 100 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.
